- Home
- SLN vs HQH Comparison
SLN vs HQH Comparison
Compare SLN & HQH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLN
- HQH
- Stock Information
- Founded
- SLN 1994
- HQH 1986
- Country
- SLN United Kingdom
- HQH United States
- Employees
- SLN N/A
- HQH N/A
- Industry
- SLN Biotechnology: Pharmaceutical Preparations
- HQH Finance Companies
- Sector
- SLN Health Care
- HQH Finance
- Exchange
- SLN Nasdaq
- HQH Nasdaq
- Market Cap
- SLN 919.6M
- HQH 933.0M
- IPO Year
- SLN N/A
- HQH N/A
- Fundamental
- Price
- SLN $18.50
- HQH $18.70
- Analyst Decision
- SLN Strong Buy
- HQH
- Analyst Count
- SLN 4
- HQH 0
- Target Price
- SLN $61.50
- HQH N/A
- AVG Volume (30 Days)
- SLN 179.3K
- HQH 183.8K
- Earning Date
- SLN 11-12-2024
- HQH 01-01-0001
- Dividend Yield
- SLN N/A
- HQH 11.56%
- EPS Growth
- SLN N/A
- HQH N/A
- EPS
- SLN N/A
- HQH 1.09
- Revenue
- SLN $22,623,125.00
- HQH N/A
- Revenue This Year
- SLN N/A
- HQH N/A
- Revenue Next Year
- SLN $104.98
- HQH N/A
- P/E Ratio
- SLN N/A
- HQH $15.24
- Revenue Growth
- SLN N/A
- HQH N/A
- 52 Week Low
- SLN $6.51
- HQH $14.31
- 52 Week High
- SLN $27.72
- HQH $17.94
- Technical
- Relative Strength Index (RSI)
- SLN 48.92
- HQH 53.53
- Support Level
- SLN $18.20
- HQH $18.22
- Resistance Level
- SLN $19.36
- HQH $18.65
- Average True Range (ATR)
- SLN 0.88
- HQH 0.20
- MACD
- SLN -0.04
- HQH 0.04
- Stochastic Oscillator
- SLN 35.50
- HQH 92.31
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid. its pipeline products are; SLN360 therapy designed to temporarily block a specific gene's message that would otherwise trigger an unwanted effect. By silencing the LPA gene, the levels of Lp(a) are lowered, which in turn is expected to lower the risks of heart diseases, heart attacks, and strokes, and SLN124 therapy aims to temporarily silence TMPRSS6, a gene that prevents the liver from producing a particular hormone that controls iron levels in the body hepcidin. As hepcidin increases, iron levels in the blood are expected to decrease, which may increase the production of healthy red blood cells, thereby reducing anemia.
About HQH abrdn Healthcare Investors Shares of Beneficial Interest
abrdn Healthcare Investors Formerly Tekla Healthcare Investors is the United States based non-diversified closed-end management investment company. Its objective is to seek long-term capital appreciation by investing in securities of healthcare companies. In addition, the fund seeks to provide regular distribution of realized capital gains. The fund invests in the securities of public and private companies.